All In Biotech

Drug Trial Radar · NCT01095731

The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage

Phase II Study of the Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage

Last checked: Nov 19, 2026Latest source record: Oct 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

60

Actual

Start

Apr 2010

Primary completion

Jul 2012

Study completion Jul 2013

Sponsor

Lead sponsor
E. Sander ConnollyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Florida; University of Washington; Food and Drug Administration (FDA)
First posted
Mar 30, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this patient population. Funding Source - FDA Office of Orphan Products Development

Conditions

  • Aneurysmal Subarachnoid Hemorrhage

Interventions

  • TioproninDrug

    Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.

  • PlaceboDrug

    Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cerebrospinal Fluid 3-aminopropanal (CSF-3AP) LevelsTime frame: Day 7

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of Florida

    Gainesville, Florida

  • Columbia University Medical Center

    New York, New York

  • University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.